2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. The Journal Of Allergy And Clinical Immunology In Practice 2016, 4: 497-504. PMID: 26895621, DOI: 10.1016/j.jaip.2015.12.019.Peer-Reviewed Original ResearchConceptsRapid drug desensitizationDrug desensitizationAllergic patientsLife expectancyMonoclonal antibodiesNonallergic control groupOptimal pharmacological agentsOverall health costsFirst-line therapyAdministration of carboplatinConnective tissue diseaseStandard of careIndividual patient reactionsDesensitized patientsNonallergic groupAllergic groupLine therapyRisk stratificationTissue diseaseHypersensitivity reactionsChronic diseasesOvarian cancerSevere reactionsNonsignificant increasePharmacological agents
2008
Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. Journal Of Allergy And Clinical Immunology 2008, 122: 574-580. PMID: 18502492, DOI: 10.1016/j.jaci.2008.02.044.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsRapid desensitizationLife-threatening hypersensitivity reactionMedical intensive care unitChemotherapeutic drugsRapid desensitization protocolRapid drug desensitizationIntensive care unitStandard of careFirst desensitizationTemporary tolerizationDesensitization protocolDrug desensitizationCare unitDrug allergensPreferred agentOutpatient settingIntraperitoneal routeSubsequent infusionLiposomal doxorubicinAllergic reactionsAlternative drugsInitial desensitizationTarget doseTreatment records